CP 336156

Known as: CP-336,156 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2005
Review
2005
  • Drugs in R&D
  • 2005
Lasofoxifene [CP 336156] is a potent, nonsteroidal, tissue-selective estrogen receptor modulator (SERM). It has the bone-sparing… (More)
Is this relevant?
2004
2004
Neuroprotective effects of estradiol are well characterized in animal experimental models. However, in humans, the outcome of… (More)
Is this relevant?
2003
2003
Selective estrogen receptor modulators (SERMs) are estrogen receptor (ER) ligands that function as antagonists in some tissues… (More)
Is this relevant?
2002
2002
Estrogen replacement therapy is reported to reduce the incidence of vertebral fractures in postmenopausal women, however, its… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 4
Is this relevant?
2001
2001
The purpose of this study was to evaluate if long-term (6 months) treatment with lasofoxifene (LAS), a new selective estrogen… (More)
Is this relevant?
2000
2000
It has been well documented that selective estrogen receptor modulators (SERMs) can prevent bone loss in ovariectomized rats and… (More)
Is this relevant?
Review
2000
Review
2000
Selective oestrogen receptor modulators (SERMs) are structurally diverse non-steroidal compounds that bind to oestrogen receptors… (More)
  • figure 1
  • table I
  • table II
  • table III
Is this relevant?
1999
1999
  • Drugs in R&D
  • 1999
 
Is this relevant?
1998
1998
We have discovered a new, nonsteroidal, potent estrogen agonist/antagonist, CP-336,156. CP-336,156 binds selectively and with… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 5
  • figure 6
Is this relevant?